Novo Nordisk’s obesity feast lacks a second course
By Aimee DonnellanThe $174 bln weight loss pioneer plans to expand in new treatments. Yet a promised extra $23 bln of revenue by 2035 will barely offset the loss of sales as its core Wegovy franchise comes off patent. And regaining ground will be hard in an obesity market fat with new competition.F…